Cullinan Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Cullinan Therapeutics, Inc. on June 26, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol CGEM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document details the outcomes of two shareholder proposals:
- Proposal One (Election of Directors): Stockholders elected two Class I directors for three-year terms.
- Anne-Marie Martin, Ph.D.: Received 25,054,060 votes for, with 11,471,277 votes withheld and 4,156,894 broker non-votes.
- David Meek: Received 36,409,849 votes for, with 115,488 votes withheld and 4,156,894 broker non-votes.
- Proposal Two (Ratification of Accounting Firm): Stockholders ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 40,163,993
- Votes Against: 516,975
- Abstentions: 1,263
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investors to Verify
- Confirmation that Anne-Marie Martin, Ph.D., and David Meek have officially assumed their roles as Class I directors.
- Verification of KPMG LLP's engagement as the independent auditor for the 2024 fiscal year.
- Review of the significant number of votes withheld for Anne-Marie Martin (approx. 31% of votes cast) compared to David Meek (approx. 3% of votes cast).